Docoh
Loading...

GRFS Grifols SA - ADR - Level III

Filed: 4 May 21, 7:28am

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934

 

For the month May 2021

 

(Commission File No. 001-35193)

 

Grifols, S.A.

(Translation of registrant’s name into English)

 

 

 

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x  Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

 

Yes ¨  No x

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

 

Yes ¨  No x

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨  No x

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-         .                       .

 

 

 

 

 

Grifols, S.A.

 

TABLE OF CONTENTS

 

Item Sequential Page Number
1.Press Release, dated May 4, 2021 3

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.First Quarter 2021 ResultsGrifols maintains its revenues and operational levels while enhancing its innovation strategy and securing its plasma supply• Grifols reports EUR 1,185 million in revenues, an operational1 decline of 0.9%. • Contributions from new products and price increases on specific plasma proteins partially offset lower sales volumes due to COVID-19 impacted lower plasma collections, bringing Bioscience Division revenues to EUR 901 million, an operational decline of 5.6%. • The Diagnostic and Hospital Divisions report solid sales revenues of EUR 203 million (28.0% cc) and EUR 31 million (4.3% cc), respectively. Bio Supplies Commercial continues to grow by double digits. • EBITDA totals EUR 322 million, excluding the impact of exchange rate variations. EBITDA margins at 25.1%. Grifols’ gross margin stands at 45.0%. • Grifols continues to strengthen its innovation strategy: Alkahest and GigaGen place Grifols on the leading edge of bioscience, while diversifying and reinforcing its R+D+i pipeline. • Grifols accelerates the execution of its expansion plan to immediately access an additional 1.4 million liters of plasma per year, while moving forward with the opening of new centers.Barcelona, May 4, 2021.- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) reported EUR 1,184.7 million in revenues in the first quarter of 2021, a decline of 0.9% cc and 8.4% taking into account exchange rate variations. The company maintained its operational levels in the first quarter despite these unprecedented times, limiting COVID-19-related impacts through contributions from new products, continuous efforts to increase plasma donations, effective inventory management, and the expansion of Grifols’ plasma collection capacity.1Operative or constant currency (cc) excludes exchange rate variations reported in the period.Page 1 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.Grifols advances in the execution of its expansion plan to increase its plasma supply by acquiring several plasma collection centers in the first quarter. These transactions enabled the company to instantly leverage an additional 1.4 million liters of plasma, approximately, per year. Grifols’ plasma collection levels in Germany were strong in the first quarter, achieving higher volumes than those recorded in the same period in 2020 and 2019. In the United States, plasma donations are gradually recovering. Of note was the trend observed in January, February and April in the wake of the country’s vaccination rollouts and the easing of COVID-19 restrictions, while taking into account the mitigating effect of stimulus incentives issued in March and December. In recent years, Grifols has forged a solid global network of 351 plasma donation centers, operating 296 centers in the United States and 55 in Europe, including Germany, Austria and Hungary. Grifols’ plasma centers network represents a significant competitive advantage, enabling the company to expand and diversify its plasma supply. Bioscience Division revenues fell by 5.6% cc (-13.3%) to EUR 901.3 million due to lower plasma collections obtained in the second and third quarters of 2020. This decline was offset by mid- single digit price increases on some of the main plasma proteins and contributions from new products (XEMBIFY®, VISTASEALTM and TAVLESSE®). The Diagnostic Division accelerated its growth, increasing by 28.0% cc (21.1%) to EUR 203.3 million in revenues. Sales of the TMA (Transcription-Mediated Amplification) molecular test, used to detect the SARS-CoV-2 virus, were noteworthy. Additionally, underlying growth of the NAT donor-screening lines (Procleix® NAT Solutions) and recombinant proteins, used to produce diagnostic immunoassays, were growth drivers for the division. The Hospital Division grew by 4.3% cc (1.7%) to EUR 31.2 million, showing signs of recovery.The Bio Supplies Division attained EUR 56.3 million in sales, declining 4.9% cc (-12.2%) due primarily to a drop in third-party plasma sales. Sales of biological products for non-therapeutic use sustained their double-digit operating growth. The gross margin remained stable at 45.0% over revenues (45.1% in the fourth quarter of 2020 and 45.7% in Q1 2020). EBITDA totaled EUR 296.8 million and EUR 321.7 million excluding exchange rate variations. EBITDA margin stands at 25.1% (26.0% in the fourth quarter of 2020 and 27.2% in Q1 2020). Grifols remains firmly committed to its innovation strategy, one of its fundamental corporate pillars. In this regard, its capacity to innovate plays an integral role in its sustainable growth plan. Grifols’ R+D+i pipeline is keenly focused on exploring diseases management beyond plasma- derived therapies. The company’s total net investment in R+D+i amounts to EUR 70.7 million, representing 6.0% of total revenues. The company’s R+D+i allocations reflect its incremental efforts to support the integration and development of both Alkahest and GigaGen projects.Page 2 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.In the first quarter of 2021, Alkahest presented the findings of the phase II clinical trial of its therapeutic plasma fraction candidate, GRF6021 at the 15ᵗʰ International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2021). The GRF6021 study included subjects with Parkinson’s disease and cognitive impairment, demonstrating the treatment’s positive effects on cognitive endpoints, as well as its safety and tolerability. Alkahest will further study the efficacy of GRF6021 to promote its clinical development. Through GigaGen, Grifols is also advancing on the discovery and early development of recombinant biotherapeutic solutions, including the world’s first recombinant polyclonal immunoglobulin. These efforts will contribute to strategically enhancing Grifols’ portfolio of cutting- edge therapies. The company’s financial results totaled EUR 58.7 million in the first quarter; EUR 73.3 million reported in the same period last year, excluding the positive accounting impact of EUR 56.5 million from the closing of the Shanghai RAAS transaction registered in that period. Equity-accounted investments in investees primarily included the updating of equity holdings in GigaGen (EUR 35.5 million) following the recent agreement to acquire its remaining shares. Net profit in the first quarter totaled EUR 129.9 million.Excluding the impact of IFRS 16³, Grifols’ net financial debt amounted to EUR 6,200.5 million and net financial debt over EBITDA ratio stood at 5.1x as a result, mainly, of the EUR 505 million paid for the BPL, Kedrion, Alkahest and GigaGen transactions. Debt management is a key priority for the company, which is making determined efforts to decrease its debt levels. Grifols has resources and liquidity to fulfill its short- and medium-term obligations. As of March 31, 2021, the company had EUR 381 million in cash positions and approximately EUR 672 million in undrawn lines of credit, placing its liquidity position in excess of EUR 1,000 million. After the refinancing process completed in November 2019, Grifols does not face significant maturities or debt repayments until 2025.³ At March 31, 2020, the impact of IFRS 16 on debt totaled EUR 786.5 million.Page 3 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.PERFORMANCE BY DIVISIONBioscience DivisionThe Bioscience Division earned EUR 901.3 million in revenues (-5.6% cc and -13.3%). Global demand of the main plasma proteins remains very solid. Lower sales of plasma-derived medicines were partially offset by mid-single digit price increases on some of the main plasma proteins, as well as contributions from new products such as Xembify®, VISTASEALTM and TAVLESSE®. Demand for immunoglobulins remains solid, led by the U.S., Canada and several markets in the European Union (EU) and Latin America. Albumin sales remained robust driven by growth in China, whose underlying demand holds significant potential for the division. To better serve the needs of its hospital and pharmacy customers, in April Grifols initiated the U.S. market launch of ALBUTEIN FlexBagTM 25%, designed for added convenience, ease of use and durability. Alpha-1 antitrypsin continues to fuel the division’s performance. Demand remained steady in the United States and higher in some European markets such as France. Despite the pandemic, the company continued its efforts to increase the rate of diagnosis and broaden its use in other countries. In this regard, worth mentioning is the product approval by Japanese health authorities in the first quarter. Grifols will join forces with a leading Japanese partner-distributor to commercialize this product, whose launch is expected in the coming months. In terms of new product releases, the company recorded strong sales of XEMBIFY® and its biological sealant, a surgical bleeding-control solution developed and manufactured by Grifols using a combination of two plasma proteins (fibrinogen and thrombin). Also worth noting are solid European sales of TAVLESSE® (fostamatinib), a medication used to treat chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. TAVLESSE® is marketed under an agreement with Rigel Pharmaceuticals. Diagnostic DivisionThe Diagnostic Division attained EUR 203.3 million in revenues, growing by 28.0% cc and 21.1% considering exchange rate variations. Grifols’ NAT systems (Procleix® NAT Solutions), which incorporate Transcription Mediated Amplification (TMA) systems to screen blood and plasma donations, were the driving forces of this underlying growth. An upswing in sales of Grifols’ specialty diagnostic test to detect the SARS-CoV-2 virus, particularly in Spain, sparked higher demand for this business line. Sales of recombinant proteins, used to manufacture diagnostic immunoassays, positively contributed to the division’s revenues. The blood-typing line, which includes both analyzers (Erytra®, Erytra-Eflexis® and Wadiana®) and reagents (DG-Gel®, red blood cells and antiserums), reported an upward trend.Page 4 of 12

 

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.In parallel, the division obtained important CE authorizations, which will boost the market expansion of certain products in Europe. These include CE marks for Procleix UltrioPlex E assay – a nucleic acid test designed to simultaneously detect the presence of HIV-1, HIV-2, hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis E virus (HEV) – and the Procleix Babesia assay, which detects the presence of several clinically relevant species of Babesia parasites. Also of note was the European market launch of a two-test point-of-care (POC) system for monitoring a patient’s level of infliximab, a medication used to treat a range of chronic inflammatory conditions, as well as to measure antibody levels that could reduce the drug’s efficacy. Hospital DivisionThe Hospital Division saw a recovery and an increase in revenues to EUR 31.2 million, growing by 4.3% cc and 1.7% taking exchange rate variations into account. Especially noteworthy were the first-quarter sales of third-party manufacturing services and the Pharmatech line, comprised by the inclusiv® portfolio of integrated technology, software, and intravenous solutions designed to improve the safety, efficiency and control of hospital pharmacy operations. Bio Supplies DivisionThe Bio Supplies Division registered EUR 56.3 million in sales in the first quarter of the year, an operational decline of 4.9% cc and 12.2% compared to the same period last year. This decrease mainly stemmed from a fall in third-party plasma sales.On the other hand, Bio Supplies Commercial revenues, which consist of sales of biological products for non-therapeutic use, grew significantly in the first three months of 2021, with a 12.1% cc upturn in sales.Page 5 of 12

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.CORPORATE TRANSACTIONS• Acquisition of 32 plasma centers in the United States: access to nearly 1.4 million additional liters of plasma per yearGrifols closed the acquisition of 32 plasma centers in the United States in the first quarter of 2021, further consolidating the leadership of its global network. The company currently operates 351 centers: 296 in the United States and 55 in Europe. Specifically, in March 2021, Grifols acquired 25 U.S.-based centers from BPL Plasma Inc. for USD 370 million, giving it immediate access to an additional 1 million liters of plasma per year. In April 2021, the company also invested USD 55 million to acquire seven U.S.-based plasma centers from Kedrion. These centers will provide roughly 240,000 million liters of plasma per year. Both operations were financed with Grifols’ own resources without issuing debt. These acquisitions reflect the company’s commitment to boost its plasma supply through organic and inorganic growth. As part of its organic efforts, Grifols anticipates opening 15 to 20 new plasma centers in 2021. Following the strategic alliance signed with the Egyptian government in November 2020, the company also plans on opening several plasma centers in Egypt in 2021. The joint venture recently inaugurated new administrative headquarters in New Cairo.• Acquisition of the remaining 56% share capital of GigaGenWithin the framework of its integrated innovation strategy, Grifols acquired the remaining 56% share capital of GigaGen Inc. for USD 80 million. GigaGen is a U.S. biotech company dedicated to the discovery and early development of recombinant biotherapeutic medicines. Its research focuses on finding new biological treatments based on antibodies derived from millions of immune system cells obtained from donors.The company has several projects in its research pipeline, including the development of the world’s first recombinant polyclonal immunoglobulin and a portfolio of immuno-oncological therapies.GigaGen brings a diversified project portfolio to develop recombinant polyclonal antibodies, including its lead asset GIGA-2050, a recombinant hyperimmune immunoglobulin to treat COVID- 19. The phase I clinical trial on GIGA-2050 is expected to launch in the U.S. in the spring of 2021 following its approval by the Food and Drug Administration (FDA) as an Investigational New Drug (IND).Page 6 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.Investor contact:Investor Relations inversores@grifols.com - investors@grifols.com Phone number: +34 93 571 02 21Media contacts: Raquel Lumbreras raquel_lumbreras@duomocomunicacion.com Borja Gómez borja_gomez@duomocomunicacion.com Duomo Comunicación Grifols PR office Phone number: +34 91 311 92 89 - 91 311 92 90KEY FINANCIAL FIGURESIn millions of euros except % and EPS1Q 20211Q 2020% VarNET REVENUES GROSS MARGIN EBITDA REPORTED % Net revenues GROUP PROFIT % Net revenues ADJUSTED⁽¹⁾ GROUP PROFIT % Net revenues1,184.7 45.0% 296.8 25.1% 129.9 11.0% 117.5 9.9%1,293.3 45.7% 351.1 27.2% 186.4 14.4% 153.1 11.8%(8.4%)(15.5%)(30.3%)(23.3%)CAPEX R&D NET INVESTMENT EARNINGS PER SHARE (EPS) REPORTED51.6 70.7 0.1960.2 83.3 0.27(14.4%) (15.1%) (30.3%)TOTAL ASSETS TOTAL EQUITY CASH & CASH EQUIVALENTS LEVERAGE RATIOMarch 2021 16,137.6 7,196.7 381.0 5.12/(5.05cc)⁽²⁾December 2020 15,274.8 6,720.1 579.6 4.52/(4.63cc)⁽²⁾% Var 5.6% 7.1% (34.3%)⁽¹⁾ Excludes non-recurring items, amortization of deferred expenses associated to the refinancing, amortization of intangible assets related to acquisitions and IFRS 16. ⁽²⁾ Constant currency (cc) excludes exchange rate fluctuations over the period.Page 7 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.PROFIT AND LOSS ACCOUNTIn thousands of euros1Q 20211Q 2020% VarNET REVENUES COST OF SALES GROSS MARGIN % Net revenues R&D SG&A OPERATING EXPENSES SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES - CORE ACTIVITIES OPERATING RESULT (EBIT) % Net revenues FINANCIAL RESULT SHARE OF RESULTS OF EQUITY ACCOUNTED INVESTEES PROFIT BEFORE TAX % Net revenues INCOME TAX EXPENSE % of pre-tax income CONSOLIDATED PROFIT RESULT ATTRIBUTABLE TO NON-CONTROLLING INTERESTS GROUP PROFIT % Net revenues1,184,734 (651,407) 533,327 45.0% (71,810) (257,141) (328,951)8,577212,953 18.0% (58,700) 34,481 188,734 15.9% (37,747) 20.0% 150,987 21,052 129,935 11.0%1,293,319 (702,085) 591,234 45.7% (67,865) (250,585) (318,450)789273,573 21.2% (16,846) (5,451) 251,276 19.4% (47,736) 19.0% 203,540 17,160 186,380 14.4%(8.4%) (7.2%) (9.8%)5.8% 2.6% 3.3%987.1%(22.2%)248.5% (732.6%) (24.9%)(20.9%)(25.8%) 22.7% (30.3%)GROUP PROFIT RECONCILIATIONIn millions of euros1Q 20211Q 2020% VarGROUP PROFIT % Net revenues Amortization of deferred financial expenses Amortization of intangible assets acquired in business combinations Non-recurring items⁽¹⁾ IFRS 16 Tax impacts ADJUSTED GROUP NET PROFIT % Net revenues129.9 11.0% 12.6 11.6 (35.5) 5.4 (6.5) 117.5 9.9%186.4 14.4% 10.7 11.3 (56.5) 6.1 (4.9) 153.1 11.8%(30.3%)17.8% 2.7% (37.2%) (11.5%) 32.7% (23.3%)⁽¹⁾ 2021 non-recurring items are related to EUR 35.5 million write-up of the equity stake in GigaGen following the acquisition of the remaining equity capital. 2020 non-recurring items were related to EUR 56.5 million capital gain related to the closing of the Shanghai RAAS transaction.Page 8 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.3M - NET REVENUE BY DIVISIONIn thousands of euros 1Q 2021 % of Net Revenues1Q 2020 % of Net Revenues% Var % Var cc*BIOSCIENCE DIAGNOSTIC HOSPITAL BIO SUPPLIES OTHERS INTERSEGMENTS901,277 203,269 31,207 56,300 7,174 (14,493)76.0% 17.2% 2.6% 4.8% 0.6% (1.2%)1,039,942 167,876 30,675 64,139 5,144 (14,457)80.4% 12.9% 2.4% 5.0% 0.4% (1.1%)(13.3%) 21.1% 1.7% (12.2%) 39.5% 0.2%(5.6%) 28.0% 4.3% (4.9%) 49.0% (5.6%)TOTAL1,184,734 100.0%1,293,319 100.0%(8.4%)(0.9%)3M - NET REVENUE BY REGIONIn thousands of euros 1Q 2021 % of Net Revenues1Q 2020 % of Net Revenues% Var % Var cc*US + CANADA EU ROW743,292 231,938 209,50462.7% 19.6% 17.7%912,151 199,599 181,56970.5% 15.5% 14.0%(18.5%) 16.2% 15.4%(10.4%) 16.6% 27.6%TOTAL1,184,734 100.0%1,293,319 100.0%(8.4%)(0.9%)* Constant currency (cc) excludes exchange rate fluctuations over the period.Page 9 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.CASH FLOWIn thousands of euros1T 20211T 2020REPORTED GROUP PROFIT129,935186,380DEPRECIATION AND AMORTIZATION NET PROVISIONS OTHER ADJUSTMENTS AND OTHER CHANGES IN WORKING CAPITAL CHANGES IN INVENTORIES CHANGES IN TRADE RECEIVABLES CHANGES IN TRADE PAYABLES CHANGE IN OPERATING WORKING CAPITAL81,774 (852) 56,028 (66,956) 42,237 (64,497) (89,216)77,574 (1,900) (60,063) (74,684) 1,344 (23,282) (96,622)NET CASH FLOW FROM OPERATING ACTIVITIES177,669105,369BUSINESS COMBINATIONS AND INVESTMENTS IN GROUP COMPANIES CAPEX R&D/OTHER INTANGIBLE ASSETS OTHER CASH INFLOW / (OUTFLOW) NET CASH FLOW FROM INVESTING ACTIVITIES(504,638) (51,556) (8,239) (2,529) (566,962)(17,999) (60,205) (26,192) (8,912) (113,308)FREE CASH FLOW(389,293)(7,939)PROCEEDS FROM / (PAYMENTS) FOR EQUITY INSTRUMENTS ISSUE / (REPAYMENT) OF DEBT OTHER CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES(23,497) 192,080 2750 (114,843) 4,804NET CASH FLOW FROM FINANCING ACTIVITIES168,858(110,039)TOTAL CASH FLOW(220,435)(117,978)CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR EFFECT OF EXCHANGE RATE CHANGES IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD579,647 21,768 380,980741,982 13,693 637,697Page 10 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.BALANCE SHEETASSETSIn thousands of eurosMarch December 2021 2020NON-CURRENT ASSETS13,052,02512,109,822GOODWILL AND OTHER INTANGIBLE ASSETS PROPERTY PLANT & EQUIPMENT INVESTMENTS IN EQUITY ACCOUNTED INVESTEES NON-CURRENT FINANCIAL ASSETS OTHER NON-CURRENT ASSETS8,357,163 2,423,071 1,896,034 233,755 142,0027,568,617 2,324,107 1,869,020 198,157 149,921CURRENT ASSETS3,085,5743,164,954INVENTORIES TRADE AND OTHER RECEIVABLES OTHER CURRENT FINANCIAL ASSETS OTHER CURRENT ASSETS CASH AND CASH EQUIVALENTS2,138,006 495,777 6,077 64,734 380,9802,002,281 520,158 11,118 51,750 579,647TOTAL ASSETS16,137,59915,274,776EQUITY AND LIABILITIESIn thousands of eurosMarch December 2021 2020EQUITY7,196,7316,720,055CAPITAL SHARE PREMIUM RESERVES TREASURY STOCK CURRENT YEAR EARNINGS OTHER COMPREHENSIVE INCOME NON-CONTROLLING INTERESTS119,604 910,728 4,395,311 (67,232) 129,935 (65,256) 1,773,641119,604 910,728 3,776,932 (43,734) 618,546 (273,684) 1,611,663NON-CURRENT LIABILITIES7,380,0107,219,583NON-CURRENT FINANCIAL LIABILITIES OTHER NON-CURRENT LIABILITIES6,730,953 649,0576,602,100 617,483CURRENT LIABILITIES1,560,8581,335,138CURRENT FINANCIAL LIABILITIES OTHER CURRENT LIABILITIES637,112 923,746424,612 910,526TOTAL EQUITY AND LIABILITIES16,137,59915,274,776Page 11 of 12

 

 

 

 

Free translation from the original in Spanish. In the event of discrepancy, the Spanish language version will prevail.About GrifolsGrifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.Grifols, with close to 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced jobs. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex- 35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit Grifols.comLEGAL DISCLAIMERThe facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.Page 12 of 12

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 Grifols, S.A.
   
   
 By:/s/ David I. Bell
  Name:David I. Bell
  Title:Authorized Signatory

 

Date:  May 4, 2021